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BACKGROUND
It is unknown whether warfarin or aspirin therapy is superior for patients with heart 
failure who are in sinus rhythm.
METHODS
We designed this trial to determine whether warfarin (with a target international 
normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better 
treatment for patients in sinus rhythm who have a reduced left ventricular ejection 
fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). 
The primary outcome was the time to the first event in a composite end point of 
ischemic stroke, intracerebral hemorrhage, or death from any cause.
RESULTS
The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin 
group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence 
interval [CI], 0.79 to 1.10; P = 0.40). Thus, there was no significant overall difference 
between the two treatments. In a time-varying analysis, the hazard ratio changed 
over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but 
this finding was only marginally significant (P = 0.046). Warfarin, as compared 
with aspirin, was associated with a significant reduction in the rate of ischemic 
stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 
100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P = 0.005). The rate of ma-
jor hemorrhage was 1.78 events per 100 patient-years in the warfarin group as 
compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intra-
cranial hemorrhage did not differ significantly between the two treatment groups 
(0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P = 0.82).
CONCLUSIONS
Among patients with reduced LVEF who were in sinus rhythm, there was no sig-
nificant overall difference in the primary outcome between treatment with warfarin 
and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was 
offset by an increased risk of major hemorrhage. The choice between warfarin and 
aspirin should be individualized. (Funded by the National Institute of Neurological 
Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.)
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Chronic heart failure is a major cause of illness and death. Heart failure is associated with a hypercoagulable state, 
formation of left ventricular thrombus, and cere-
bral embolism.1,2 It is also associated with both 
sudden death and death resulting from progressive 
heart failure that may be caused by unrecognized 
atherothrombotic events.3 As a result, there is a ra-
tionale for using oral anticoagulants to treat pa-
tients with chronic heart failure who are in sinus 
rhythm. However, the role of oral anticoagulants 
as compared with aspirin has not been clarified in 
patients with chronic heart failure.4-6 Early studies 
showed that anticoagulation reduced the rates of 
embolic events and death, but many patients in 
these trials had atrial fibrillation and clinically sig-
nificant valvular heart disease, making interpre-
tation of the results difficult.7-9 In retrospective 
analyses of data from large trials involving pa-
tients with a reduced left ventricular ejection 
fraction (LVEF), conflicting results have been re-
ported.10-13 Unfortunately, these findings are of 
limited value, since the use of anticoagulants was 
not randomized or controlled, data were collect-
ed retrospectively, end points were not predefined 
or standardized, and patients with atrial fibrilla-
tion were included.
Several prospective studies comparing oral anti-
coagulants with aspirin were too small to provide 
conclusive evidence for the superiority of either 
agent.14-16 In the Heart Failure Long-Term Anti-
thrombotic Study (HELAS), 197 patients were ran-
domly assigned to warfarin, aspirin, or placebo; 
there was no significant difference among the 
groups in the incidence of embolic events.14 In the 
Warfarin/Aspirin Study in Heart Failure (WASH), 
279 patients were randomly assigned to warfarin, 
aspirin, or placebo; there was no significant dif-
ference among the groups in the composite end 
point of death, stroke, or myocardial infarction, 
but the rate of hospitalization was highest among 
those receiving aspirin.15 The Warfarin and An-
tiplatelet Therapy in Chronic Heart Failure trial 
(WATCH), which was the most recent and the 
largest study, enrolled 1587 patients who were 
randomly assigned to warfarin, aspirin, or clopi-
dogrel, with a mean follow-up period of 1.9 
years.16 The results of this trial, which was ter-
minated prematurely owing to difficulties with 
recruitment, suggested that there was a reduc-
tion in the rate of ischemic stroke with warfarin 
as compared with aspirin but showed an increase 
in hospitalization for heart failure in the aspirin 
group as compared with the warfarin group. The 
Warfarin versus Aspirin in Reduced Cardiac Ejec-
tion Fraction (WARCEF) trial was designed to 
compare the efficacy and safety of warfarin with 
those of aspirin among a substantially larger num-
ber of patients, with the use of a double-blind, 
randomized design.17
Me thods
Study Design and Oversight
We conducted a cooperative, double-blind, multi-
center clinical trial at 168 centers in 11 countries. 
The trial was sponsored by the National Institutes 
of Health (NIH), with an independently funded 
clinical coordinating center and statistical analysis 
center. Warfarin and warfarin placebo were pro-
vided by Taro Pharmaceuticals U.S.A., and aspirin 
and aspirin placebo by Bayer HealthCare. Neither 
of these companies had any role in the design of 
the study, the collection or analysis of the data, the 
writing of the manuscript, or the decision to sub-
mit the manuscript for publication. The target in-
ternational normalized ratio (INR) was 2.75, with 
an acceptable target range of 2.0 to 3.5. To mini-
mize variations in blood processing, blood samples 
for determination of the INR were processed at 
selected central laboratories. To confirm the ac-
curacy of LVEF assessment, personnel at two core 
echocardiography laboratories (in St. Louis and 
New York) who were unaware of the treatment 
assignments reviewed the echocardiographic stud-
ies. An independent end-point adjudication com-
mittee, whose members were unaware of the treat-
ment assignments, adjudicated all primary and 
secondary outcomes and major hemorrhages. The 
trial protocol, available with the full text of this 
article at NEJM.org, was approved by the institu-
tional review board at each participating center. 
The first two authors assume responsibility for the 
completeness and accuracy of the data and analy-
ses and for the fidelity of the study to the protocol. 
Written informed consent was obtained from each 
patient. Patient recruitment started in October 
2002 and ended in January 2010. The maximum 
follow-up time was 6 years, and the minimum was 
1 year. An independent data and safety monitor-
ing board appointed by the NIH monitored trial 
operations.
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Study Patients
Eligible patients were 18 years of age or older and 
had normal sinus rhythm, no contraindication to 
warfarin therapy, and an LVEF of 35% or less as 
assessed by quantitative echocardiography (or a 
wall-motion index of ≤1.2) or as assessed by ra-
dionuclide or contrast ventriculography within 
3 months before randomization. Patients who had 
a clear indication for warfarin or aspirin were not 
eligible. Patients in any New York Heart Associa-
tion (NYHA) functional class were eligible, but pa-
tients in NYHA class I could account for no more 
than 20% of the total number of patients under-
going randomization. Additional eligibility criteria 
were a modified Rankin score of 4 or less (on a 
scale of 0 to 6, with higher scores indicating more 
severe disability), and planned treatment with a 
beta-blocker, an angiotensin-converting–enzyme 
(ACE) inhibitor (or, if the side-effect profile with 
ACE inhibitors was unacceptable, with an angioten-
sin-receptor blocker), or hydralazine and nitrates. 
Patients were ineligible if they had a condition that 
conferred a high risk of cardiac embolism, such as 
atrial fibrillation, a mechanical cardiac valve, endo-
carditis, or an intracardiac mobile or pedunculat-
ed thrombus.
Study Medication
In the double-blind, double-dummy design, pa-
tients who were assigned to active warfarin re-
ceived warfarin and placebo aspirin, and patients 
assigned to active aspirin received aspirin and pla-
cebo warfarin.18 The statistical analysis center fab-
ricated clinically plausible INR results for patients 
in the aspirin group and provided these results to 
the sites, along with the actual INR results for the 
patients in the warfarin group, so that all the pa-
tients were treated as if they were receiving active 
warfarin.
Follow-up
Follow-up was performed monthly by telephone or 
in person at the time blood was obtained for de-
termination of the INR, to assess adherence to the 
study drug and to regulate INR values. A follow-
up assessment in person was also conducted quar-
terly for a clinical evaluation and annually for a 
detailed examination. All data were entered into 
the Web-based communications interface that was 
developed and managed by the statistical analysis 
center.
Assessment of Outcomes and Major Adverse 
Events
The primary outcome was the time to the first 
event in a composite end point of ischemic stroke, 
intracerebral hemorrhage, or death from any cause. 
Stroke was defined as a clinically relevant new 
lesion detected on computed tomography or mag-
netic resonance imaging (MRI) or, in the absence 
of a new lesion, clinical findings that were con-
sistent with the occurrence of clinical stroke and 
that lasted for longer than 24 hours. The main 
secondary outcome was the first event in a com-
posite of the primary outcome, myocardial infarc-
tion, or hospitalization for heart failure. Major 
hemorrhage was defined as intracerebral, epidural, 
subdural, subarachnoid, spinal intramedullary, or 
retinal hemorrhage; any other bleeding causing a 
decline in the hemoglobin level of more than 2 g 
per deciliter in 48 hours; or bleeding requiring 
transfusion of 2 or more units of whole blood, hos-
pitalization, or surgical intervention. Minor hemor-
rhage was defined as any nonmajor hemorrhage.
Statistical Analysis
The primary null hypothesis was that the time to 
the first event in the composite primary end point 
(ischemic stroke, intracerebral hemorrhage, or 
death from any cause) would not differ significant-
ly between the group receiving warfarin therapy 
and the group receiving aspirin therapy. The main 
secondary null hypothesis was that the time to the 
first event of the primary outcome, myocardial in-
farction, or hospitalization for heart failure would 
not differ significantly between the two groups.
The original target sample size was 2860 pa-
tients, providing 89% power to test the primary 
null hypothesis in the intention-to-treat popula-
tion, with the use of a log-rank test and a two-
sided probability of a type I error of 5%, assuming 
a hazard rate reduction of 17.82% in either group 
as compared with the other, after adjustment for 
use or nonuse of beta-blockers and allowance for 
discontinuation of therapy, dropout, and crossover 
(e.g., owing to the development of atrial fibrilla-
tion). In 2009, because of slow recruitment, a plan 
was developed to stop recruitment in 2010 and to 
extend the maximum follow-up time from 5 years 
to 6 years, resulting in a projected sample size of 
2303 and power of approximately 65%. The final 
sample of 2305 patients yielded a sufficient num-
ber of outcomes for the study to have 69% power 
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Table 1. Baseline Characteristics of the Study Participants, According to Treatment Group.*
Characteristic Warfarin (N = 1142) Aspirin (N = 1163)
Age — yr 61±11.6 61±11.1
Location — no. (%)
North America 573 (50.2) 546 (46.9)
Europe 527 (46.1) 567 (48.8)
Argentina 42 (3.7) 50 (4.3)
Male sex — no./total no. (%) 904/1140 (79.3) 936/1160 (80.7)
Race or ethnic group — no./total no. (%)†
Non-Hispanic white 857/1140 (75.2) 876/1159 (75.6)
Non-Hispanic black 166/1140 (14.6) 166/1159 (14.3)
Hispanic 85/1140 (7.5) 81/1159 (7.0)
Other 32/1140 (2.8) 36/1159 (3.1)
Height — cm 172±9.3 172±9.2
Weight — kg 86±19.6 87±19.3
Body-mass index‡
Mean 29±5.9 29±6
Distribution — no./total no. (%)
<25 294/1135 (25.9) 265/1149 (23.1)
25–30 426/1135 (37.5) 456/1149 (39.7)
>30 415/1135 (36.6) 428/1149 (37.2)
Blood pressure — mm Hg
Systolic 124±19.3 124±18.4
Diastolic 74±11.6 74±11.3
Pulse — beats/min 72±11.4 72±12.5
Hypertension — no./total no. (%) 671/1104 (60.8) 696/1128 (61.7)
Diabetes mellitus — no./total no. (%) 371/1138 (32.6) 351/1156 (30.4)
Atrial fibrillation — no./total no. (%) 44/1139 (3.9) 42/1156 (3.6)
Myocardial infarction — no./total no. (%) 549/1138 (48.2) 563/1156 (48.7)
Ischemic cardiomyopathy — no./total no. (%) 488/1138 (42.9) 503/1155 (43.5)
Pulmonary or other embolism — no./total no. (%) 28/1139 (2.5) 24/1155 (2.1)
Smoking status — no./total no. (%)
Current smoker 213/1138 (18.7) 195/1158 (16.8)
Former smoker 581/1138 (51.1) 599/1158 (51.7)
Never smoked 344/1138 (30.2) 364/1158 (31.4)
Alcohol consumption — no./total no. (%)
Current consumption, >2 oz/day 279/1140 (24.5) 293/1158 (25.3)
Previous consumption, >2 oz/day 250/1140 (21.9) 256/1158 (22.1)
Never consumed alcohol 611/1140 (53.6) 609/1158 (52.6)
Educational level — no./total no. (%)
<High school 490/1140 (43.0) 502/1155 (43.5)
High-school graduate or some college 487/1140 (42.7) 460/1155 (39.8)
College graduate or postgraduate 163/1140 (14.3) 193/1155 (16.7)
NYHA classification — no./total no. (%)§
I 150/1137 (13.2) 165/1153 (14.3)
II 621/1137 (54.6) 646/1153 (56.0)
III 351/1137 (30.9) 329/1153 (28.5)
IV 15/1137 (1.3) 13/1153 (1.1)
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to test the primary null hypothesis and 83% power 
for the main secondary null hypothesis.
Both major study hypotheses were prespecified 
and were tested according to the intention-to-treat 
principle at a two-tailed alpha level of 0.05. For 
the test of the primary null hypothesis, the statis-
tical analysis plan prespecified the use of a log-
rank test to compare the cumulative incidence 
Table 1. (Continued.)
Characteristic Warfarin (N = 1142) Aspirin (N = 1163)
Ejection fraction — % 25±7.5 25±7.5
Distance covered on 6-minute walk — m¶ 346±147.3 356±152.5
Prior stroke or TIA — no./total no. (%) 155/1138 (13.6) 139/1157 (12.0)
Score on modified Rankin scale — no./total no. (%)‖
All patients
0 463/1133 (40.9) 489/1157 (42.3)
1 353/1133 (31.2) 359/1157 (31.0)
2 262/1133 (23.1) 266/1157 (23.0)
3 46/1133 (4.1) 40/1157 (3.5)
4 9/1133 (0.8) 3/1157 (0.3)
Patients with prior stroke or TIA
0 40/154 (26.0) 38/139 (27.3)
1 50/154 (32.5) 43/139 (30.9)
2 48/154 (31.2) 48/139 (34.5)
3 12/154 (7.8) 9/139 (6.5)
4 4/154 (2.6) 1/139 (0.7)
Medications — no./total no. (%)**
Aspirin†† 611/1047 (58.4) 632/1071 (59.0)
Other antiplatelet agent†† 32/428 (7.5) 40/461 (8.7)
Warfarin or other oral anticoagulant†† 90/1142 (7.9) 89/1163 (7.7)
ACE inhibitor or ARB 1118/1136 (98.4) 1139/1157 (98.4)
Beta-blocker 1026/1136 (90.3) 1036/1158 (89.5)
Aldosterone blocker 406/666 (61.0) 407/679 (59.9)
Nitrate 284/1135 (25.0) 259/1158 (22.4)
Calcium-channel blocker 100/1135 (8.8) 103/1156 (8.9)
Diuretic 925/1136 (81.4) 930/1158 (80.3)
Statin 690/827 (83.4) 704/851 (82.7)
Device — no./total no. (%)
Pacemaker 141/1139 (12.4) 144/1156 (12.5)
Implantable cardioverter–defibrillator 212/1139 (18.6) 206/1156 (17.8)
*  Plus–minus values are means ±SD. None of the differences between the warfarin group and the aspirin group were signifi-
cant (P>0.05). Continuous variables were compared with the use of Student’s t-test. Binary categorical variables were com-
pared with the use of Fisher’s exact test, and multicategory variables were compared with the use of standard chi-square 
tests. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and TIA transient ischemic attack.
†  Race and ethnic group were self-reported separately and were combined for presentation.
‡  The body-mass index is the weight in kilograms divided by the square of height in meters.
§  The New York Heart Association (NYHA) classification groups patients with heart failure according to the extent of 
limitation during physical activity. Class I indicates no limitation, and class IV severe limitation.
¶  Data on the distance covered on a 6-minute walk were available for 2102 (1031 in the warfarin group and 1071 in the 
aspirin group) of the 2305 patients (91.2%).
‖  Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms and 6 indicating death. In this 
study, the scores ranged from 0 to 4; a score higher than 4 was a protocol-specified criterion for exclusion.
** Data on medications were obtained from the case-report form at the screening visit.
†† Data on aspirin and other antiplatelet agents and warfarin or other oral anticoagulants are for the use of these medi-
cations before the patients underwent randomization.
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curves in the treatment groups if log-minus-log 
survival curves did not show a violation of the 
proportional-hazards assumption and a Cox model 
with time-varying hazard ratios if they did. Since 
the log-minus-log survival curves crossed, we re-
port the results of the log-rank test as the primary 
analysis and, secondarily, the results from the Cox 
model, which expresses the log-relative hazard 
ratio as a linear function of follow-up time. A pre-
specified interim monitoring procedure was per-
formed according to the method of Haybittle and 
Peto, with conservative stopping boundaries for 
the interim analyses of log-rank z scores in excess 
of ±3.2905 (corresponding to a nominal two-tailed 
P value of 0.001). Because very little type I error was 
spent with this procedure, we report only the un-
adjusted P values. Hazard ratios for individual 
components of the outcomes were obtained from 
cause-specific proportional-hazards models with 
or without time-varying coefficients, depending on 
their statistical significance at an alpha level of 
0.05. To help weigh overall risks and benefits, we 
conducted a post hoc safety analysis that added 




From October 2002 through January 2010, a total of 
2305 patients were enrolled (1119 in the United 
States and Canada and 1186 in Europe and Ar-
gentina). The mean [±SD] follow-up time was 
3.5±1.8 years, and the total follow-up time was 
8225 patient-years. The clinical and demographic 
characteristics of the patients are shown in Table 
1. Survival status was known for 97.0% of the 
patients. A total of 34 patients (1.5%) withdrew 
consent, and 35 (1.5%) were lost to follow-up.
Laboratory Testing
The mean LVEF for the entire study population 
was 24.7±7.5%, with no significant difference be-
tween the warfarin and aspirin groups. Echocar-
diographic studies from 1854 of the 2305 patients 
in the study population (80.4%) were analyzed at 
the core echocardiography laboratories; 1746 of 
these patients (94.2%) had an LVEF of 35% or less 
or a wall-motion index of 1.2 or less. Baseline 
contrast angiography, radionuclide scanning, or 
MRI confirmed the eligibility of 239 of the 2305 
patients (10.4%), and the remaining 212 patients 
(9.2%) entered the study with echocardiographic 
confirmation of LVEF or wall-motion-index values 
at the local site, without the core laboratory review.
After a 6-week period of dose adjustment, pa-
tients in the warfarin group had an INR in the 
therapeutic range, defined as 2.0 to 3.5, for 62.6% 
of the follow-up time, as calculated with the use 
of a modification of the method of Rosendaal.19 
INR values were below 2.0 for 27.1% of the total 
treatment time and above 3.5 for 10.3% of the 
total treatment time. In the warfarin group, the 
mean INR value during treatment was 2.5±0.95.
Outcomes
Overall, 622 of the 2305 patients (27.0%) had a 
primary outcome (531 deaths [85.4%], 84 ischemic 
strokes [13.5%], and 7 intracerebral hemorrhages 
[1.1%]) (Table 2). The rates of the primary outcome 
were 7.47 events per 100 patient-years in the warfa-
rin group and 7.93 per 100 patient-years in the aspi-
rin group, with no significant difference between 
the two groups (hazard ratio with warfarin, 0.93; 
95% confidence interval [CI], 0.79 to 1.10; P = 0.40) 
(Fig. 1). A time-varying analysis with the use of a 
Cox model showed a small benefit of warfarin as 
compared with aspirin over time. The hazard ratio 
decreased by a factor of 0.89 per year (95% CI, 














































Figure 1. Cumulative Incidence of the Primary Outcome.
The primary outcome was the time to the first event in the composite end 
point of ischemic stroke, intracerebral hemorrhage, or death from any cause.
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significant by year 4 (hazard ratio with warfarin, 
0.76; P = 0.04) (Fig. 2).
In the entire patient population, there was a 
constant and significant benefit with warfarin as 
compared with aspirin with respect to the rate 
of ischemic stroke (hazard ratio, 0.52; 95% CI, 
0.33 to 0.82; P = 0.005) (Table 2). The two treat-
ment groups did not differ significantly with re-
spect to the rate of intracerebral hemorrhage. Pa-
tients in the warfarin group did not receive the 
randomly assigned medication (and instead re-
ceived open-label therapy) for 34% of the total 
follow-up time, and patients in the aspirin group 
did not receive the assigned medication for 32% 
of the time. With respect to the main secondary 
outcome (first event in the composite of death, 
ischemic stroke, intracerebral hemorrhage, myo-
cardial infarction, or hospitalization for heart 
failure), there was no significant difference be-
tween the warfarin group and the aspirin group 
(hazard ratio with warfarin, 1.07; 95% CI, 0.93 
to 1.23; P = 0.33). The rates of myocardial infarc-
tion and hospitalization for heart failure did not 
differ significantly between the two groups, al-
though there was a trend toward a higher rate of 
hospitalization for heart failure in the warfarin 
group (P = 0.053) (Table 2).
The rate of major hemorrhage was significantly 
higher with warfarin than with aspirin (1.78 events 
per 100 patient-years with warfarin vs. 0.87 per 
100 patient-years with aspirin; adjusted rate ratio, 
2.05; 95% CI, 1.36 to 3.12; P<0.001) (Table 3). 
However, the rates of intracerebral and intracranial 
hemorrhages combined did not differ signifi-
cantly according to treatment group (0.27 events 
per 100 patient-years in the warfarin group and 
0.22 per 100 patient-years in the aspirin group, 
P = 0.82). Major gastrointestinal bleeding occurred 
more frequently in the warfarin group (0.94 events 
per 100 patient-years vs. 0.45 per 100 patient-years 
in the aspirin group, P = 0.01). Table S1 in the 
Supplementary Appendix (available at NEJM.org) 
shows the most frequent and the most clinically 
relevant serious adverse events according to treat-
ment group.
Discussion
The WARCEF trial was designed to determine 
whether warfarin or aspirin is a better treatment 
for patients with a reduced LVEF who are in sinus 
rhythm. Previous studies either were retrospective 
or lacked the power to adequately address this is-
sue. As a result, there has been insufficient evi-
dence to support any strong treatment recommen-
dations regarding the use of warfarin or aspirin in 
these patients. Our trial had a double-blind design 
with sham INRs, similar to that used in the War-
farin–Aspirin Recurrent Stroke Study (WARSS, 
NCT00027066), and used centralized INR process-
ing centers to ensure that the INR data would be 
of high quality.18,20
Our results show no significant overall differ-
ence between warfarin and aspirin therapies in 
preventing the primary outcome. Although there 
may have been a small benefit with warfarin 
among patients followed for 4 or more years, it was 
of borderline statistical significance and uncer-
tain clinical significance. There was a consistent 
and significant benefit of warfarin as compared 
with aspirin with respect to the prevention of is-
chemic stroke throughout the follow-up period. 











































Figure 2. Hazard Ratios for the Primary Outcome with Warfarin, According to 
Year of Follow-up.
Hazard ratios were estimated with the use of a stratified Cox model that ex-
pressed the log-relative hazard ratio as a linear function of follow-up time. 
The hazard ratio decreased by a factor of 0.89 per year (95% confidence in-
terval, 0.80 to 0.998; P = 0.046). I bars indicate 95% confidence intervals.
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and has now been confirmed in the WARCEF trial, 
which included more patients and a longer follow-
up period.16 However, the benefit was offset by the 
increase in the incidence of major bleeding. The 
relative reduction in the risk of ischemic stroke 
with warfarin among the patients in our study, 
who had heart failure, is similar to that observed 
among patients with atrial fibrillation.21 However, 
the absolute risk of ischemic stroke among pa-
tients with a low LVEF who are in sinus rhythm 
is significantly lower than that among patients 
with atrial fibrillation.16
With respect to the main secondary outcome, 
which included myocardial infarction and hospi-
talization for heart failure, in addition to the 
primary outcome, there was no significant differ-
ence between the warfarin group and the aspirin 
group. There was a trend toward an increased rate 
of hospitalization for heart failure in the warfarin 
group, a finding that is in direct contrast to the 
results of the WASH and WATCH trials, which sug-
gested an increased rate of hospitalization for 
heart failure among patients receiving aspirin.15,16 
There has been speculation that aspirin may in-
Table 3. Rates of Hemorrhage and Death, According to Treatment Group.*
Event Warfarin (N = 1142) Aspirin (N = 1163)
Odds Ratio or Rate  
Ratio (95% CI)† P Value‡
Death as part of primary outcome — no. of patients (%)
From any cause 268 (23.5) 263 (22.6) 1.05 (0.86–1.27) 0.66
Related to hemorrhage§ 7 (0.6) 4 (0.3) 1.84 (0.54–6.32) 0.38
Death after primary outcome — no. of patients (%)¶
After ischemic stroke 5 (0.4) 7 (0.6) 0.71 (0.22–2.40) 0.77
After intracerebral hemorrhage 2 (0.2) 2 (0.2) 0.98 (0.11–9.10) 1.00
Major hemorrhage — no. of patients (%)‖ 66 (5.8) 31 (2.7) 2.21 (1.42–3.47) <0.001
Intracerebral 5 (0.4) 2 (0.2) 2.52 (0.52–17.9) 0.29
Intracranial** 5 (0.4) 7 (0.6) 0.72 (0.22–2.43) 0.77
Gastrointestinal 37 (3.2) 16 (1.4) 2.35 (1.30–4.38) 0.005
Other 21 (1.8) 7 (0.6) 3.06 (1.26–7.57) 0.008
Minor hemorrhage — no. of patients (%) 280 (24.5) 189 (16.3) 1.65 (1.34–2.05) <0.001
All hemorrhages††
Total no. of patient-yr 4044.7 4032.8
Major hemorrhage — no. of events (no./100 patient-yr) 72 (1.78) 35 (0.87) 2.05 (1.36–3.12) <0.001
Intracerebral 5 (0.12) 2 (0.05) 2.48 (0.51–17.6) 0.45
Intracranial** 6 (0.15) 7 (0.17) 0.86 (0.29–2.85) 1.00
Gastrointestinal 38 (0.94) 18 (0.45) 2.10 (1.19–3.70) 0.010
All other 23 (0.57) 8 (0.2) 2.88 (1.30–6.94) 0.01
Minor hemorrhage — no. of events (no./100 patient-yr) 468 (11.6) 296 (7.34) 1.56 (1.34–1.81) <0.001
*  The maximum follow-up time was 74.3 months. Hemorrhages that occurred on the day of the primary event (death, ischemic stroke, or 
intracerebral hemorrhage) are included.
†  Odds ratios are shown for all categories with number and percent of patients; rate ratios are shown for all categories with number of 
events and rate per 100 person-years. Odds ratios and rate ratios are conditional maximum-likelihood estimates, stratified according to 
geographic location (North America, Europe, or Argentina). No test for heterogeneity of odds ratios or rate ratios across geographic loca-
tions was significant at the 0.05 level; the smallest P value for heterogeneity was 0.08 for the rate of minor hemorrhage.
‡  P values for categories with number and percent of patients were calculated with the use of the exact test of two independent proportions, 
stratified according to geographic location. P values for categories with number of events and rate per 100 patient-years were calculated 
with the use of the exact conditional binomial test for two independent Poisson variables, stratified according to geographic location.
§  Included are major hemorrhages that occurred within 30 days before the patient died.
¶  These deaths are not primary end points and are not included in the total number of deaths in this table or in Table 2.
‖  Included is the first or only hemorrhage for each patient.
** Intracranial hemorrhages include intracranial or spinal hemorrhages, subarachnoid hemorrhages, subdural or epidural hemorrhages, and 
retinal hemorrhages.
†† Included are all hemorrhages that occurred in any patient.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 29, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;20 nejm.org may 17, 20121868
terfere with prostaglandin synthesis, leading to 
a reduced effectiveness of ACE inhibition.22,23 In 
our trial, however, no increase in the rate of 
hospitalization for heart failure was seen in the 
aspirin group as compared with the warfarin 
group, even though a large proportion of patients 
in the aspirin group were treated with an ACE 
inhibitor.
In the warfarin group, the INR was in the 
therapeutic range of 2.0 to 3.5 for 63% of the 
total treatment time. We set the INR target above 
that used in trials involving patients with atrial 
fibrillation, because among trials involving pa-
tients who had had a myocardial infarction, 
those with higher INR targets and values showed 
the superiority of warfarin over aspirin, whereas 
those with lower INR targets and values did 
not.24,25 In our study, patients received either war-
farin or aspirin and did not take both medica-
tions. The side-effect profile in the case of both 
warfarin and aspirin was generally acceptable, 
and there was a low rate of intracerebral hemor-
rhage. The rate of major hemorrhage was signifi-
cantly increased with warfarin therapy but was 
lower than that seen in the warfarin group in 
recent trials involving patients with atrial fibril-
lation and similar to that seen in the WARSS and 
WATCH trials.16,20,26,27
The limitations of our study include the smaller-
than-anticipated number of patients enrolled, and, 
given the variable length of follow-up, the rela-
tively small numbers of patients who were still 
being followed in years 5 and 6. The time in the 
therapeutic range among patients in the warfarin 
group was relatively low at 63%. In addition, in 
both groups, there was a substantial portion of 
follow-up time during which the patients did not 
receive the assigned study treatment. However, this 
duration was similar in the two treatment groups, 
thus minimizing any bias. Since newer antithrom-
botic agents, as compared with warfarin, are easier 
to administer and may be associated with better 
long-term adherence to therapy, they may increase 
the time in the therapeutic range and reduce the 
time during which patients do not receive the 
assigned therapy.26-28 If so, they may prove to be 
more effective than warfarin or aspirin.
In summary, this trial showed no significant 
overall difference between warfarin and aspirin 
with respect to the primary outcome of death, 
ischemic stroke, or intracerebral hemorrhage. 
However, among patients followed for 4 or more 
years, there may have been a small benefit, of 
uncertain clinical significance, with warfarin. 
Warfarin was associated with a reduction in the 
risk of ischemic stroke throughout the follow-up 
period. Given the finding that warfarin did not 
provide an overall benefit and was associated with 
an increased risk of bleeding, there is no compel-
ling reason to use warfarin rather than aspirin in 
patients with a reduced LVEF who are in sinus 
rhythm.
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